SCHEMBL2292071

SCHEMBL2292071

COc1cccc(OCC(N)=O)c1-c1nc2ccccn2c1Nc1c(Cl)cccc1Cl

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 4/20 0.41
TP53 P04637 4/20 0.41
ALDH1A1 P00352 3/20 0.41
HPGD P15428 3/20 0.41
TUBB4A P04350 5/20 0.40
TUBB P07437 5/20 0.40
TUBA3C P0DPH7 5/20 0.40
TUBA1B P68363 5/20 0.40
TUBA4A P68366 5/20 0.40
TUBB4B P68371 5/20 0.40
TUBB3 Q13509 5/20 0.40
TUBB2A Q13885 5/20 0.40
TUBB8 Q3ZCM7 5/20 0.40
TUBA3E Q6PEY2 5/20 0.40
TUBA1A Q71U36 5/20 0.40
TUBA1C Q9BQE3 5/20 0.40
TUBB6 Q9BUF5 5/20 0.40
TUBB2B Q9BVA1 5/20 0.40
TUBB1 Q9H4B7 5/20 0.40
MAPT P10636 5/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2292734 0.95 GAA (0.46) SMN1; SMN2TP53ALDH1A1HPGDTUBB4A
SCHEMBL2294935 0.90 MAPT (0.52) SMN1; SMN2TP53ALDH1A1HPGDTUBB4A
SCHEMBL2294341 0.89 GAA (0.40) SMN1; SMN2TP53ALDH1A1HPGDTUBB4A
SCHEMBL2295458 0.87 GAA (0.51) SMN1; SMN2TP53ALDH1A1HPGDMAPT
SCHEMBL2288547 0.87 SMN1; SMN2 (0.43) SMN1; SMN2TP53ALDH1A1HPGDTUBB4A
SCHEMBL2291876 0.87 MAPT (0.47) SMN1; SMN2TP53ALDH1A1HPGDTUBB4A
SCHEMBL2289439 0.84 ADRA1B (0.46) SMN1; SMN2TP53ALDH1A1HPGDTUBB4A
SCHEMBL2293580 0.84 GAA (0.55) SMN1; SMN2TP53ALDH1A1HPGDMAPT
SCHEMBL2290892 0.83 GAA (0.49) SMN1; SMN2TP53ALDH1A1HPGDMAPT
SCHEMBL2287179 0.81 GAA (0.50) SMN1; SMN2TP53ALDH1A1HPGDTUBB4A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2032571-B1 3 -AMINO-IMIDAZO[1, 2-A]PYRIDINE DERIVATIVES AS SGLT INHIBITORS MERCK PATENT GMBH (DE) 2014-12-03 EP claimed
US-8258151-B2 3-aminoimidazo [1,2-A] pyridine derivatives as SGLT inhibitors MERCK PATENT GMBH (DE) 2012-09-04 US claimed
US-20110195991-A1 3-AMINOIMIDAZO [1,2-A] PYRIDINE DERIVATIVES AS SGLT INHIBITORS MERCK PATENT GESELLSCHAFT (DE) 2011-08-11 US claimed
EP-2032571-B1 3 -AMINO-IMIDAZO[1, 2-A]PYRIDINE DERIVATIVES AS SGLT INHIBITORS MERCK PATENT GMBH (DE) 2014-12-03 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110195991-A1 3-AMINOIMIDAZO [1,2-A] PYRIDINE DERIVATIVES AS SGLT INHIBITORS GLP1R, SLC5A1, SLC5A2 SMN1; SMN2 3644/4885TP53 4410/4885ALDH1A1 778/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.